These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19688158)

  • 41. Erythema multiforme during anti-tumor necrosis factor treatment for plaque psoriasis.
    Ahdout J; Haley JC; Chiu MW
    J Am Acad Dermatol; 2010 May; 62(5):874-9. PubMed ID: 19913942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis.
    Saraceno R; Schipani C; Mazzotta A; Esposito M; Di Renzo L; De Lorenzo A; Chimenti S
    Pharmacol Res; 2008 Apr; 57(4):290-5. PubMed ID: 18400510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful treatment of hand and foot psoriasis with efalizumab therapy.
    Fretzin S; Crowley J; Jones L; Young M; Sobell J
    J Drugs Dermatol; 2006 Oct; 5(9):838-46. PubMed ID: 17039648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 45. Successful use of infliximab following a failed course of etanercept in a pediatric patient.
    Farnsworth NN; George SJ; Hsu S
    Dermatol Online J; 2005 Dec; 11(3):11. PubMed ID: 16409907
    [No Abstract]   [Full Text] [Related]  

  • 46. Successive sebopsoriasis, erysipelas and Koebner phenomenon.
    Viguier M; Bachelez H
    CMAJ; 2010 Apr; 182(6):E252. PubMed ID: 20212027
    [No Abstract]   [Full Text] [Related]  

  • 47. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis.
    Safa G; Loppin M; Bousser AM; Barbarot S
    J Am Acad Dermatol; 2007 Feb; 56(2 Suppl):S19-20. PubMed ID: 17097376
    [No Abstract]   [Full Text] [Related]  

  • 48. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab.
    Strober BE
    Arch Dermatol; 2004 Mar; 140(3):366. PubMed ID: 15023789
    [No Abstract]   [Full Text] [Related]  

  • 49. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis.
    Esposito M; Gisondi P; Cassano N; Babino G; Cannizzaro MV; Ferrucci G; Chimenti S; Giunta A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S31-4. PubMed ID: 25381971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biological agents in the treatment of psoriasis.
    Tzu J; Krulig E; Cardenas V; Kerdel FA
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Biological treatment of psoriasis and psoriatic arthritis].
    Kragballe K; Deleuran B
    Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Tutrone WD
    Cutis; 2003 Jan; 71(1):41-5. PubMed ID: 12553629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
    Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
    Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
    [No Abstract]   [Full Text] [Related]  

  • 56. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.
    Krell JM
    J Am Acad Dermatol; 2006 Jun; 54(6):1099-101. PubMed ID: 16713481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efalizumab-associated papular psoriasis.
    Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
    Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytomegalovirus infection in a patient treated with efalizumab for psoriasis.
    Miquel FJ; Colomina J; Maríi JI; Ortega C
    Arch Dermatol; 2009 Aug; 145(8):961-2. PubMed ID: 19687445
    [No Abstract]   [Full Text] [Related]  

  • 59. Exacerbation of psoriasis under efalizumab therapy.
    Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
    J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
    Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D;
    Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.